Studying Blood Immune Cells and Insulin Resistance in Teenagers
Collects blood samples and health information from teens at risk of diabetes.
Plain-language title generated from the registry record
Registry title: Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Key facts
- Where
- Ann Arbor, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 18 years old?
Source: NCT06007404, who can take part
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Michigan
- Trial code
- NCT06007404
- Record updated
- 15 October 2026
- Original description
This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.Read full original descriptionShow less
The Role of Circulating Meta-Inflammatory Monocytes in Adolescent Insulin Resistance
This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.
Inclusion: Between 14 and 18 years of age; Tanner stage 4 or 5 (mature adult stage of puberty); Normal weight (BMI ≥ 5th percentile \& < 85th percentile), overweight (BMI > 86th percentile) \& < 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and/or pre-diabetes (HbA1c > 5.7%); For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes.
Exclusion: Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff; Allergies or intolerance to milk, soy, or palm oil; Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management; Currently pregnant.